Methotrexate 500mg/5mL (100mg/mL) Injection

Methotrexate 500mg/5mL (100mg/mL) is an injectable antifolate used in selected cancer regimens. Oncology use can involve doses and rescue requirements very different from low-dose weekly inflammatory-disease treatment.
It is administered by the route and timed schedule of the oncology protocol. High-dose regimens require hydration, urine alkalinisation, measured methotrexate clearance and scheduled folinic-acid rescue.
Methotrexate interferes with folate-dependent cellular pathways. Low-dose treatment reduces inflammatory immune activity, while oncology regimens inhibit proliferation of susceptible rapidly dividing cells.
Nausea, mouth ulcers, fatigue, low blood counts, raised liver enzymes and injection-site discomfort can occur. Kidney injury and lung inflammation are important risks. Fever, unusual bruising, severe mouth ulcers, dry cough or breathlessness needs urgent assessment.
Blood counts, kidney and liver function are monitored. Pregnancy exposure can cause fetal harm. Trimethoprim or co-trimoxazole can markedly increase marrow toxicity, and NSAIDs or other interacting medicines may impair clearance. Injectable products are not automatically suitable for intrathecal use; preservative content and presentation matter.
Provides folate-pathway inhibition against susceptible malignant cells as part of the specified regimen.
No. Cancer regimens can use substantially different doses, routes and rescue procedures.
It protects healthy cells after high-dose methotrexate; its timing follows the treatment and clearance results.
They help reduce precipitation of methotrexate in the kidneys and support elimination.
No. Intrathecal use requires an explicitly suitable preservative-free presentation and a dedicated protocol.
Antifolate: a medicine interfering with folate-dependent processes. Folinic-acid rescue: protection of healthy cells after specific regimens. Clearance: removal of a medicine from the body.; AR: Methotrexate 500mg/5mL (100mg/mL) حقن; FR: Methotrexate 500mg/5mL (100mg/mL) injection; PT: Methotrexate 500mg/5mL (100mg/mL) injeção; ES: Methotrexate 500mg/5mL (100mg/mL) inyección; RU: Methotrexate 500mg/5mL (100mg/mL) инъекция; ID: Methotrexate 500mg/5mL (100mg/mL) injeksi; VI: Methotrexate 500mg/5mL (100mg/mL) thuốc tiêm; MS: Methotrexate 500mg/5mL (100mg/mL) suntikan; TL: Methotrexate 500mg/5mL (100mg/mL) iniksyon; ZH-SG: Methotrexate 500mg/5mL (100mg/mL) 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Methotrexate 500mg/5mL (100mg/mL) Injection under Oncology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Methotrexate 500mg/5mL (100mg/mL) Injection